Viva Biotech

Viva Biotech offers comprehensive one-stop services encompassing early-stage structure-based drug research and development through to commercial manufacturing. The company leverages advanced capabilities in Structure-Based Drug Discovery (SBDD), utilizing technologies such as X-ray crystallization, Cryo-EM, DEL, and AIDD/CADD. Their integrated platform supports both small molecules and biologics, providing extensive medicinal chemistry services, from hit-to-lead optimization to custom synthesis, alongside integrated CDMO solutions via its subsidiary, Langhua Pharma.

The company was established in 2008 by founders Cheney Mao, Feng Mao Hua, and Ying Wu. Their founding insight centered on creating a specialized contract research organization focused on structure-based drug discovery, recognizing its pivotal role and broad applicability as a core technological approach within the pharmaceutical landscape. This strategic foundation allowed Viva Biotech to build expertise in a critical area of drug development.

Viva Biotech primarily serves global biopharmaceutical innovators and high-potential startups. The company's vision is to become a long-term partner and a collaborative platform for innovative biotech companies around the world. It aims to facilitate drug discovery and development efforts, ultimately contributing to the creation of novel therapies that address unmet medical needs.